agree with this. Current pricing would operate the company at a...

agree with this. Current pricing would operate the company at a breakeven depending on the "bed penetration rate".
It's quite straightforward maths when you look at the number of beds Painchek need to be breakeven.

Probably a better metric for "break even" would be cashflow positive as cash determines whether a company raise capital or not..
That metric depends entirely on the operations spend and capex spend so there would be more variables to consider.

All in all I hope Painchek eventually get the FDA approval and open a larger market to sell their product.
That's the critical crux for the investment thesis if they can't acheive the penetration rates in existing markets (AU,UK).